Entrada Therapeutics (TRDA) Liabilities and Shareholders Equity (2020 - 2026)

Entrada Therapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $335.5 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 31.03% year-over-year to $335.5 million in Q1 2026; TTM through Mar 2026 was $1.6 billion, a 26.74% decrease from a year earlier, with the FY2025 full-year figure at $377.4 million, down 28.3% from the prior year.
• Liabilities and Shareholders Equity eased to $335.5 million in Q1 2026 per TRDA's latest filing, from $377.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $582.0 million in Q2 2024 and bottomed at $252.1 million in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $469.2 million (2023), against an average of $429.3 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 107.31% in 2022 and plunged 31.03% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $252.1 million in 2022, then surged by 86.15% to $469.2 million in 2023, then advanced by 12.18% to $526.3 million in 2024, then fell by 28.3% to $377.4 million in 2025, then slipped by 11.09% to $335.5 million in 2026.
• Per Business Quant, the three latest TRDA Liabilities and Shareholders Equity figures stand at $335.5 million (Q1 2026), $377.4 million (Q4 2025), and $412.9 million (Q3 2025).